Literature DB >> 34305277

Precision medicine: Uses and challenges.

Nardeep Naithani1, Amar Tej Atal2, T V S V G K Tilak3, Biju Vasudevan4, Pratibha Misra5, Sharmila Sinha6.   

Abstract

Precision medicine has brought in many changes to the practise of medicine. The omics-based development of biomarkers and pharmaco-omics-based drug development programmes are evidences for the advancement. However, the field where it has proved to be most useful is in the development of various modalities of treatment in oncology. Various drugs targeting vascular endothelial growth factor, epidermal growth factor, tyrosine kinase receptor and rat sarcoma mutations have come to the forefront proving to be beneficial in many cancers. Some of the classic drugs developed using this concept include trastuzumab, bevacizumab, cetuximab and panitumumab among others. Precision medicine has been put to best use in the COVID-19 pandemic through use of various biomarkers such as IL-6 and c-reactive protein in assessing severity of disease, for development of various therapies and also to judge efficacy of vaccines. Precision medicine is also finding its place in management of infectious diseases, chronic diseases such as asthma, connective tissue diseases, cardiovascular diseases, diabetes and obesity. India has also made its presence felt in the field by launching various initiatives such as the Indian genome project and Indian cancer genome atlas. Numerous challenges still exist to the future of precision medicine such as cost involved, ethics, security of the Big data, merger of various platforms to integrate data and also availability of trained manpower to manage the data and algorithms. This new age medicine is a big step forward for mankind and hopefully it will bring more benefits for both patients and the caregivers in the near future.
© 2021 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.

Entities:  

Keywords:  Challenges; Emergency Medicine; Oncology; Precision medicine

Year:  2021        PMID: 34305277      PMCID: PMC8282516          DOI: 10.1016/j.mjafi.2021.06.020

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  38 in total

Review 1.  "Omics" data and levels of evidence for biomarker discovery.

Authors:  Debashis Ghosh; Laila M Poisson
Journal:  Genomics       Date:  2008-09-14       Impact factor: 5.736

Review 2.  Crizotinib and testing for ALK.

Authors:  Alice T Shaw; Benjamin Solomon; Mari Mino Kenudson
Journal:  J Natl Compr Canc Netw       Date:  2011-12       Impact factor: 11.908

3.  The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers.

Authors:  Zhen Zhang; Daniel W Chan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-20       Impact factor: 4.254

4.  Cox-2 and Her2/neu co-expression in invasive bladder cancer.

Authors:  Elke Eltze; Christian Wülfing; Dagmar Von Struensee; Hansjürgen Piechota; Horst Buerger; Lothar Hertle
Journal:  Int J Oncol       Date:  2005-06       Impact factor: 5.650

5.  Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units.

Authors:  Carol Jean Saunders; Neil Andrew Miller; Sarah Elizabeth Soden; Darrell Lee Dinwiddie; Aaron Noll; Noor Abu Alnadi; Nevene Andraws; Melanie LeAnn Patterson; Lisa Ann Krivohlavek; Joel Fellis; Sean Humphray; Peter Saffrey; Zoya Kingsbury; Jacqueline Claire Weir; Jason Betley; Russell James Grocock; Elliott Harrison Margulies; Emily Gwendolyn Farrow; Michael Artman; Nicole Pauline Safina; Joshua Erin Petrikin; Kevin Peter Hall; Stephen Francis Kingsmore
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

6.  HER-2/neu expression: a major prognostic factor in endometrial cancer.

Authors:  D J Hetzel; T O Wilson; G L Keeney; P C Roche; S S Cha; K C Podratz
Journal:  Gynecol Oncol       Date:  1992-11       Impact factor: 5.482

Review 7.  Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease.

Authors:  Merin E Kuruvilla; F Eun-Hyung Lee; Gerald B Lee
Journal:  Clin Rev Allergy Immunol       Date:  2019-04       Impact factor: 8.667

Review 8.  Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks.

Authors:  Shengda Lin; Yi A Yin; Xiaoqian Jiang; Nidhi Sahni; Song Yi
Journal:  Biomed Res Int       Date:  2016-06-14       Impact factor: 3.411

9.  Definition and application of precision medicine.

Authors:  Zheng-Guo Wang; Liang Zhang; Wen-Jun Zhao
Journal:  Chin J Traumatol       Date:  2016-10-01

10.  MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.

Authors:  Hatem Soliman; Varsha Shah; Gordan Srkalovic; Reshma Mahtani; Ellis Levine; Blanche Mavromatis; Jayanthi Srinivasiah; Mohamad Kassar; Robert Gabordi; Rubina Qamar; Sarah Untch; Heather M Kling; Tina Treece; William Audeh
Journal:  BMC Cancer       Date:  2020-01-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.